Single-Cell Sequencing Market Size, Share & Forecast 2026-2032
Single-cell sequencing: $2.19B in 2026 to $4.37B by 2032 at 12.2%. Published 2025 estimates span 1.51x, tested against 10x Genomics' disclosed revenue.
$2.2B
$4.4B
12.2%
Global
Executive Summary
Single-cell sequencing is one of the few markets in this corpus where the published sizings broadly agree — and that agreement is the least interesting thing about it. Within the sequencing-only scope, 2025 estimates run from Towards Healthcare's $1.88 billion to 360iResearch's $2.83 billion, a 1.51x spread. Cross into 'single-cell analysis' and the same figure becomes $3.81 to $6.73 billion, because flow cytometry, cell sorting and imaging instruments get folded in. MarketsandMarkets publishes both scopes and its own two numbers sit 1.95x apart in the same base year, which settles whether this is a definitional artefact or a real disagreement. We publish the narrow scope: $2.19 billion in 2026 rising to $4.37 billion by 2032 at 12.2%, derived by advancing that house's own 2025 base at its own rate, and corroborated to within 1.4% by Towards Healthcare's independently published 2026 figure of $2.16 billion. The more important finding is what happens when the published totals meet a disclosed one. 10x Genomics reports Single Cell separately from Spatial and consumables separately from instruments: FY2025 Single Cell revenue was $385.9 million, which is 19.8% of the published $1.95 billion market. In that same year 10x's Single Cell consumables revenue fell 2% and its Single Cell instrument revenue fell 36%. A 12.2% whole-market rate therefore requires the non-leading four-fifths of the market — mostly private, pre-revenue or materially smaller platforms — to compound at roughly 16% a year. Every published forecast in this market is, in substance, a forecast about research funding recovering. None of them says so.
Key Highlights
Headline
$2.19 billion in 2026 to $4.37 billion in 2032 at 12.2%, derived from MarketsandMarkets' published $1.95 billion 2025 base and its own stated rate
Published 2025 sizings span 1.51x within the sequencing scope ($1.88B-$2.83B) and 3.58x once 'single-cell analysis' definitions are included ($1.88B-$6.73B)
One house, MarketsandMarkets, publishes figures 1.95x apart for the two scopes in the same base year — the clearest available proof the gap is definitional
10x Genomics' disclosed FY2025 Single Cell revenue of $385.9 million is 19.8% of the published $1.95 billion 2025 market, by our own division
The leader's Single Cell consumables revenue fell 2% and its Single Cell instruments fell 36% in FY2025, against published whole-market CAGRs of 12.2% to 16.7%
A 12.2% rate requires $1.51 billion of net market addition by 2030 — about 3.9x 10x's entire FY2025 Single Cell revenue
No vendor market shares, regional splits or country splits are published here, because no named source discloses them
Market Overview
Market Context
Single-cell sequencing sits between two much larger markets and is routinely confused with both. Upstream, the sequencing itself runs on Illumina, Pacific Biosciences and Oxford Nanopore instruments: Illumina's FY2025 revenue was $4.34 billion, and the sequencing consumables consumed by a single-cell library are booked there, not by the single-cell vendor whose kit prepared it. Downstream and adjacent, spatial biology resolves the same molecules with tissue coordinates rather than cell identity, and at least one house folds spatial transcriptomics into its single-cell segmentation. The result is a category whose boundaries are drawn differently by every publisher and by no vendor. What makes it tractable is that 10x Genomics splits its reporting the way the market should be defined — Single Cell separately from Spatial, consumables separately from instruments — so a reader can test a published total against a disclosed one. That test is the organising argument of this report. It also explains why a market with pervasive scientific adoption (31,041 PubMed records for the method) has a commercial size measured in low single-digit billions: almost all of it is research-use-only, grant-funded, and attached to no reimbursement code.
Single-cell sequencing is the set of chemistries, instruments and analysis software that resolve genomes, transcriptomes and epigenomes one cell at a time rather than averaging a tissue. Published sizings for 2025 run from $1.88 billion to $2.83 billion on the sequencing-only scope — a 1.51x spread, unusually tight for this sector — but widen to 3.58x once houses relabel the category 'single-cell analysis' and fold in flow cytometry, cell sorting and imaging. MarketsandMarkets publishes both scopes and its own two figures sit 1.95x apart in the same base year, which settles the question of whether this is a definitional gap or a disagreement about the market. We publish the narrower scope at the lowest published rate in its cluster, because the category leader's disclosed revenue tells a slower story than any published forecast.
Market Stage
Growth
Adoption Level
Routine in research, early in clinical use
Key Trends
Market Forecast & Data
Base Year (2026)
$2.2B
Forecast (2032)
$4.4B
CAGR (2026-2032)
12.2%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $2.19B |
| 2027 | $2.46B |
| 2028 | $2.76B |
| 2029 | $3.09B |
| 2030 | $3.47B |
| 2031 | $3.89B |
| 2032 | $4.37B |
Our 12.2% is the lowest rate published in the sequencing cluster, and we chose it deliberately, because the grounding arithmetic shows even that rate runs ahead of the disclosed run-rate. MarketsandMarkets' own series requires the market to add $1.51 billion between 2025 and 2030 — roughly 3.9x 10x Genomics' entire FY2025 Single Cell revenue of $385.9 million. In the same period that forecast was published, 10x's Single Cell consumables revenue declined 2% and its Single Cell instrument revenue declined 36%. With 10x at 19.8% of the published total by our own division, the arithmetic requires the remaining ~80% to compound at about 16% a year. The houses forecasting 15.05% and 16.7% are making a correspondingly larger claim from a correspondingly different base. The honest reading is that these are not extrapolations of momentum but forecasts about three specific things: academic and government capital budgets recovering, consumables pull-through continuing to compound on an installed base that stopped growing, and cell-therapy manufacturing emerging as a non-grant-funded buyer. Our series models a constant 12.2% because that is the published rate we are using; the real path will be flatter near term and steeper later, if those three conditions hold. Readers sizing a business on this market should treat the first two forecast years as the leader's disclosed trajectory, not as our curve.
Market Dynamics
- An installed instrument base that generates recurring consumables revenue independently of new placements — the mechanism behind 10x's +3% consumables against -39% instruments in FY2025
- Tumour heterogeneity and immune-repertoire questions that bulk sequencing cannot answer, which makes single-cell the default method in oncology and immunology research (31,041 PubMed records for 'single-cell RNA sequencing' as of 16 October 2026)
- Falling cost per cell as combinatorial-indexing chemistries compete with droplet microfluidics, which widens the addressable experiment rather than the addressable customer
- Cell and gene therapy development, where release and characterisation work requires per-cell resolution on products that are themselves cells
- Sequencing capacity that is already paid for: high-throughput platforms installed for other purposes absorb single-cell libraries at marginal cost, removing a capital barrier
Market Segmentation
By Type
- Reagents and kits (pre-sequencing)
- Reagents and kits (sequencing)
- Instruments and platforms
- Software and data analysis
- Services
By End User
- Academic and research institutions
- Pharmaceutical and biotechnology companies
- Contract research organisations
- Clinical and diagnostic laboratories
By Application
- Oncology
- Immunology and infectious disease
- Neuroscience
- Stem cell and developmental biology
- Cell and gene therapy development
- Microbiology and host-pathogen interaction
Competitive Landscape
10x Genomics, Inc.
Pleasanton, California, United States
Droplet-microfluidic Chromium platform. FY2025 (preliminary, unaudited, 11 January 2026): Single Cell consumables $363.2 million (down 2%) and Single Cell instruments $22.7 million (down 36%). Also the largest spatial vendor. Received $44.1 million in patent-litigation settlement payments in the first half of 2025.
Illumina, Inc.
San Diego, California, United States
FY2025 revenue $4.34 billion, flat year-over-year; Q4 sequencing consumables $755 million, up 8%. Acquired SomaLogic from Standard BioTools for $350 million cash plus up to $75 million in milestones, completed 30 January 2026, extending the company into proteomics.
Becton, Dickinson and Company
Franklin Lakes, New Jersey, United States
BD Biosciences supplies cartridge-based single-cell multi-omic workflows alongside the flow-cytometry hardware that the wider 'single-cell analysis' market definitions count.
Standard BioTools Inc.
South San Francisco, California, United States
Reported FY2025 continuing-operations revenue of $85.3 million on 24 February 2026, down from roughly $185 million including SomaLogic. Exited the year with about $550 million in cash and investments after divesting SomaLogic to Illumina, and has stated an inorganic growth intent.
Parse Biosciences, Inc.
Seattle, Washington, United States
Instrument-free split-pool barcoding chemistry positioned against droplet microfluidics. Named here because the published whole-market forecasts require the non-10x majority of the market to compound at roughly 16% a year, and this is the kind of company that would have to do it.
Scale Biosciences, Inc.
San Diego, California, United States
Kit-based single-cell and single-nucleus chemistries, including joint RNA and ATAC assays, run on standard laboratory equipment.
Recent Developments
Reported preliminary unaudited FY2025 results on 11 January 2026 showing Single Cell consumables revenue of $363.2 million, down 2% year-over-year, and Single Cell instrument revenue of $22.7 million, down 36%, with total company revenue of approximately $598.7 million excluding $44.1 million of patent-litigation settlement receipts.
Completed the acquisition of SomaLogic from Standard BioTools on 30 January 2026 for $350 million in cash plus up to $75 million in near-term milestones and royalties, adding aptamer-based proteomics to its multiomics portfolio.
Reported FY2025 continuing-operations revenue of $85.3 million on 24 February 2026, having fully operationalised over $40 million of annualised cost savings, and disclosed roughly $550 million in cash and investments following the SomaLogic divestiture.
Reported FY2025 revenue of $4.34 billion, flat year-over-year, with fourth-quarter sequencing consumables of $755 million, up 8%, and guided FY2026 revenue to $4.5-4.6 billion.
Regulatory Landscape
Research Methodology
Secondary research
- 10x Genomics, Inc., Form 8-K Exhibit 99.1, preliminary unaudited Q4 and FY2025 revenue results, 11 January 2026 (SEC EDGAR, CIK 1770787)
- MarketsandMarkets, 'Single Cell Sequencing Market — Global Forecast to 2030', report BT 9503, published 30-31 July 2025
- Towards Healthcare, 'Single Cell Sequencing Market Sizing', last updated 07 September 2026
- Global Market Insights, single-cell analysis market (wider scope, retained for the scope comparison)
- Illumina, Inc., fourth-quarter and fiscal-year 2025 financial results, 5 February 2026
- Standard BioTools Inc., Form 8-K Exhibit 99.1, Q4 and FY2025 financial results, 24 February 2026
- PubMed (NCBI E-utilities esearch, db=pubmed), term '"single-cell RNA sequencing"', retrieved 16 October 2026: 31,041 records
- Association for Molecular Pathology v. FDA, U.S. District Court for the Eastern District of Texas, order vacating the laboratory-developed tests final rule, 31 March 2025
Validation: The headline is one house's own published base advanced at that house's own published rate, labelled as interpolation: MarketsandMarkets' $1.95B (2025) becomes $2.19B (2026) and $4.37B (2032) at 12.2%. The modelled 2030 point, $3.47B, lands within 0.3% of that house's separately published $3.46B for 2030, which confirms the interpolation is faithful rather than merely arithmetic. Independent corroboration comes from a different house: Towards Healthcare's own published 2026 figure of $2.16B is 1.4% from our derived $2.19B. The grounding calculation divides 10x Genomics' disclosed FY2025 Single Cell revenue of $385.9 million ($363.2M consumables plus $22.7M instruments, from the 11 January 2026 Form 8-K) by the published $1.95 billion 2025 total and gets 19.8%, which rules the sequencing-scope figures in as consistent with one disclosing leader holding about a fifth, and shows that the published 12.2% rate requires the market to add about 3.9x that leader's entire Single Cell revenue in five years while that leader's own Single Cell line declined 2%. That is a plausibility and run-rate test, not a market estimate: it does not establish the correct market size, the ratio is our own division against a third party's denominator, and no vendor discloses kit or library volume against which the total could be independently checked. Regional and country splits are published as empty because no named source gives a percentage; vendor shares are omitted because none is disclosed.
Strategic Takeaways
Check which scope a published figure uses before comparing it to anything. 'Single-cell sequencing' and 'single-cell analysis' differ by roughly 2x in the same base year from the same publisher, and the wider one counts flow cytometry.
$385.9 million in FY2025, with consumables down 2% and instruments down 36%.
Treat every published CAGR here as a forecast about research-funding recovery. A 12.2% rate needs about 3.9x the leader's entire current Single Cell revenue added in five years, and the leader is currently shrinking.
Do not add a published single-cell figure to a published spatial figure. At least one house counts spatial transcriptomics inside single-cell, and none states what it has excluded.
Expect consumables and instruments to keep diverging. Instruments are capital spend and move with budgets; consumables are pull-through on the installed base and are the durable revenue line.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Agriculture & Food TechBiotech Cell‑Based Meat & Alternative Protein Market$5.0B · 12% CAGR
- BiotechnologyCAR-T Cell Therapy Market$5.5B · 14.6% CAGR
- BiotechnologyGlobal Cell & Gene Therapy Manufacturing Market$5.7B · 12.2% CAGR
- BiotechnologyEurope Cell & Gene Therapy Manufacturing Market$1.8B · 13.5% CAGR
- BiotechnologyNorth America Cell & Gene Therapy Manufacturing Market$1.2B · 16% CAGR
- BiotechnologyAsia Pacific Cell & Gene Therapy Manufacturing Market$5.7B · 16.2% CAGR